Fund moves
259KShares reported
10 tracked managers disclosed the same change for Q3 2025. Among this manager's largest new positions for Q3 2025.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Sep 29, 2025 · Filed Sep 30, 2025
The CEO of Gilead Sciences sold $220K of Gilead Sciences shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$220,454
Shares × reported transaction price
53 days after results of Aug 7, 2025, 31 days before results of Oct 30, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $112.62 on Sep 29, 2025, 34% above its 52-week low and 7% below its high, after a 5% drop over the previous 30 trading days
52-week range $84.17 (Oct 3, 2024) to $120.47 (Aug 11, 2025), 78% of the way up, from 248 adjusted closes. 30 trading days earlier: $118.37 on Aug 15, 2025. Describes the past only, not a forecast
A WARN layoff notice covering 17 workers was filed in California on November 12, 2025.
From the official state WARN list, 44 days after the trade; 1 more notice by the company within 60 days. Shown for timing only; the two filings are separate
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +6.4% | +0.7% | +5.7% |
| 30 days | +7.8% | +2.0% | +5.7% |
| 90 days | +10.8% | +2.8% | +8.0% |
| 180 days | +22.7% | −5.5% | +28.1% |
| 365 days | +32.7% | +14.3% | +18.4% |
Past results only. Not a forecast.
Fund moves
10 tracked managers disclosed the same change for Q3 2025. Among this manager's largest new positions for Q3 2025.
Fund moves
75 tracked managers disclosed the same change for Q3 2025. From a 13F filed Oct 30, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Daniel Patrick O'day (Chairman & CEO) sold ~$954K of Gilead Sciences
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.